Pulmonary Diseases
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Access critical global pharma market intelligence on pulmonary diseases, including R&D, regulatory updates, and investment opportunities for BD teams.
Showing 1–2 of 2 articles
Quick answer
NovaPharmaNews Pulmonary Diseases hub for FDA covers 2 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Trump Administration Strips Job Protections of Top NIH Officials: What Pharma Teams Must Know
Addex Therapeutics GABAB PAM Shows Promise for IPF-Related Chronic Cough in Preclinical Study
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.